Absence of CYP2B6 promoter-82T>C mutation in Chinese as an additional factor for slow metabolism of drugs commonly used in infections

被引：3
|
作者：
He, Ming-liang
Lin, C. K.
Tong, Kenneth
Xu, Bingying
Sung, Joseph J. Y.
Kung, Hsiang-fu
Lee, Shui-shan [1 ]
机构：
[1] Chinese Univ Hong Kong, Ctr Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China
[3] Hong Kong Red Cross Blood Transfus Serv, Hong Kong, Hong Kong, Peoples R China
[4] Kunming Med Coll, Kunming, Yunnan Province, Peoples R China
来源：
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 2006年 / 62卷 / 07期
关键词：
Malaria; Artemisinin; Efavirenz; C64T Polymorphism; Promoter Polymorphism;
D O I：
10.1007/s00228-006-0163-6
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：585 / 586
页数：2
相关论文
共 16 条
  • [1] Absence of CYP2B6 promoter −82T>C mutation in Chinese as an additional factor for slow metabolism of drugs commonly used in infections
    Ming-liang He
    CK Lin
    Kenneth Tong
    Bingying Xu
    Joseph JY Sung
    Hsiang-fu Kung
    Shui-shan Lee
    European Journal of Clinical Pharmacology, 2006, 62 : 585 - 586
  • [2] Allelic and Genotype Frequencies of CYP2B6*2 (64C > T) and CYP2B6*3 (777C > A) in Three Dominant Ethnicities of the Iranian Population
    Khavandegar, Armin
    Tavakoli-Far, Bahareh
    Ansari, Sarina
    Veis-Karami, Parisa
    Ghasemi, Faezeh
    Sheibaninia, Samira
    Jazayeri, Roshanak
    Houshmand, Massoud
    GENETICS RESEARCH, 2023, 2023
  • [3] Pyrosequencing™-based screening for the genetic polymorphism CYP2B6 1459 C>T
    Doehring, Alexandra
    Loetsch, Joern
    PHARMACOGENOMICS, 2009, 10 (10) : 1577 - 1579
  • [4] CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations
    Carr, Daniel F.
    Chaponda, Mas
    Castro, Elena M. Cornejo
    Jorgensen, Andrea L.
    Khoo, Saye
    Van Oosterhout, Joep J.
    Dandara, Collet
    Kampira, Elizabeth
    Ssali, Francis
    Munderi, Paula
    Lalloo, David G.
    Heyderman, Robert S.
    Pirmohamed, Munir
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (12) : 3329 - 3334
  • [5] Aberrant splicing caused by single nucleotide polymorphism c.516G> T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver
    Hofmann, Marco H.
    Blievernicht, Julia K.
    Klein, Kathrin
    Saussele, Tanja
    Schaeffeler, Elke
    Schwab, Matthias
    Zanger, Ulrich M.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 325 (01): : 284 - 292
  • [6] A natural CYP2B6 TATA box polymorphism (-82T→C) leading to enhanced transcription and relocation of the transcriptional start site
    Zukunft, J
    Lang, T
    Richter, T
    Hirsch-Ernst, KI
    Nussler, AK
    Klein, K
    Schwab, M
    Eichelbaum, M
    Zanger, UM
    MOLECULAR PHARMACOLOGY, 2005, 67 (05) : 1772 - 1782
  • [7] Association of the CYP2B6 c.516G>T Polymorphism with High Blood Propofol Concentrations in Women from Northern Greece
    Mastrogianni, Orthodoxia
    Gbandi, Emma
    Orphanidis, Amvrosios
    Raikos, Nikolaos
    Goutziomitrou, Evangelia
    Kolibianakis, Efstratios M.
    Tarlatzis, Basil C.
    Goulas, Antonis
    DRUG METABOLISM AND PHARMACOKINETICS, 2014, 29 (02) : 215 - 218
  • [8] Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by CYP2B6 c.516G>T Genotypes
    Abdullahi, Sa'ad T.
    Soyinka, Julius O.
    Olagunju, Adeniyi
    Bolarinwa, Rahman A.
    Olarewaju, Olusola J.
    Bakare-Odunola, Moji T.
    Winterberg, Markus
    Tarning, Joel
    Owen, Andrew
    Khoo, Saye
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (03)
  • [9] Genetic variability (785A > G, 516G > T and 64C > T) in the CYP2B6 gene among individuals in Southwest Nigeria: Implications for malaria treatment
    Bamikole, Oluwayemi J.
    Ademola, Subulade A.
    Agatha-Christie, Dibia
    Yellow, Sandy Imo
    Etim, Joshua
    Ajige, Abdul-Lucky
    Amodu, Olukemi K.
    HUMAN GENE, 2022, 34
  • [10] CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes
    Hidestrand, M
    Oscarson, M
    Salonen, JS
    Nyman, L
    Pelkonen, O
    Turpeinen, M
    Ingelman-Sundberg, M
    DRUG METABOLISM AND DISPOSITION, 2001, 29 (11) : 1480 - 1484
12